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ABSTRACT
Background and Objectives: Endoscopic drainage/debridement of symptomatic walled off necrosis (WON) using
lumen‑apposing metal stents (LAMS) is both safe and effective. While endoscopic management of WON is the standard
approach to treatment, the ideal concomitant medical therapy remains unclear. The purpose of this study was to further
elucidate the effect of proton pump inhibitor (PPIs) therapy on the technical and clinical success of endoscopic treatment
of WON. Methods: Two hundred and seventy‑two patients in 8 centers with WON managed by endoscopic drainage using
LAMS were evaluated. Patients were followed for at least 6 months following treatment. The patients were divided into two
groups: Those that used PPIs continuously during the therapy and those not on PPIs continuously during the interval of therapy.
Outcomes included but were not limited to technical success, clinical success, number of procedures performed, and adverse
events. Results: From 2013 to 2016, 272 patients underwent WON drainage with successful transmural LAMS placement.
The two groups were split evenly into PPI users and non‑PPI users, and matched in regards to demographics, etiology of
pancreatitis, WON size, and location. There was no difference in the technical success between the two groups (100% vs.
98.8%, P = 1), or in clinical success rates (78.7% vs. 77.9%). There was a significant difference in the required number of
direct endoscopic necrosectomies to achieve clinical success in the PPI vs. non‑PPI group (3.2 vs. 4.6 respectively, P < 0.01).
There were significantly more cases of stent occlusion in the non‑PPI group vs. PPI group (9.5% vs. 20.1% P = 0.012), but
all other documented adverse events were not significantly different. Conclusion: Discontinuing PPIs during endoscopic
drainage and necrosectomy of symptomatic WON appears to reduce the number of endoscopic procedures required to achieve
resolution. Continuous PPI results in higher rates of early stent occlusion.
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INTRODUCTION
Pancreatic fluid collections (PFCs), including walled‑off
necrosis (WON), commonly occur as a complication
of pancreatitis and represent a therapeutic challenge
for clinicians. EUS‑guided drainage of WON is well
established as first‑line therapy, most commonly through
lumen apposing metal stents (LAMS) to allow drainage
of necrotic material into the stomach and access
for direct endoscopic necrosectomy (DEN). The
EUS‑guided endoscopic approach is demonstrably
as effective as surgical and percutaneous techniques
but has been shown to have lower cost and lower
morbidity.[1,2]
Several studies have demonstrated high technical
and clinical success rates with endoscopic drainage
and debridement of WON.[3,4] While the endoscopic
approach is now the first line, there still remains
some uncertainty regarding ideal simultaneous medical
therapy. Currently, some physicians use concurrent
acid suppression therapy in the form of proton pump
inhibitors (PPIs), which presumably allows a healthier
communicating tract and may reduce the rates of
certain adverse events, including bleeding and gastric
ulceration. However, PPI use leads to less acidic gastric
contents, which may retard the rate of dissolution of
solid necrotic debris.
The aim of this study was to examine the use of PPI
therapy in patients undergoing direct necrosectomy
for the treatment of WON. This is the first study to
investigate the utility of PPI therapy in these patients.
METHODS
We performed a multicenter, retrospective study of
patients with WON of the pancreas who received
LAMS between December 2013 and December 2016.
Medical records, endoscopy reports, laboratory results,
radiologic studies, and other records were reviewed for
all patients included in this study.
WON was defined as per revised Atlanta classification,
which was determined by cross‑sectional imaging and/
or EUS.[5] Necrosectomy and LAMS placement were
performed at the discretion of the clinician. Indications
for treatment included but were not limited to infected
WON, gastric outlet or biliary obstruction, refractory
abdominal pain, ongoing systemic illness, anorexia, or
persistent weight loss. Collected data included patient

demographics, cause of pancreatitis, WON size and
location, and procedure details including the number of
endoscopic procedures, diameter of LAMS used, and
supplemental techniques.
Patients included in the study were divided into two
groups: Patients on PPIs continuously during the
interval of therapy, and those not on PPIs continuously
during therapy. Outcome data included clinical and
technical success of the procedure, number of DEN
interventions required, and adverse events. The technical
success was defined as completion of transmural
stent placement and subsequent drainage of WON.
Clinical success was defined as resolution of WON
on follow‑up imaging without the need for further
intervention. IRB approval was obtained for this study.
While individual informed consents are not required
at our centers for retrospective (no cost, no risk, and
no patient contact) studies such as this, institutional
protocols and consent forms include patient consent to
having their data used in research studies.
All values are presented as mean, median (range), or
percentage. The primary outcomes of this study were
to evaluate the technical success and clinical outcomes
between the PPI and non‑PPI groups. Secondary
outcomes were patient adverse events and the number
of endoscopic necrosectomy session required to achieve
clinical success in the two groups. Data were analyzed
using cross tabulation. Categorical variables were
evaluated using Mantel–Haenszel Chi‑Square or Fisher’s
exact test, where appropriate. Continuous data were
compared using the unpaired t‑test or Mann–Whitney
tests. All values were presented as means ± standard
deviation Statistical significance was determined a priori
at P ≤ 0.05. Stepwise logistic regression was performed
using SAS V9.1 (SAS Institute, Cary, NC, USA).

Endoscopic technique

All endoscopic procedures were performed by experienced
endoscopists. Broad spectrum antibiotics were used
intraprocedurally and for 3–5 days following the
procedure. All endoscopic drainage procedures were
performed transmurally using a LAMS. A linear array
EUS was used to locate the WON collection and identify
an adequate site of the puncture. If a first‑generation
LAMS system was used, cyst puncture was generally
conducted using the Seldinger technique, using a balloon
dilator to dilate the tract to 4–6 mm. A LAMS delivery
system (AXIOS™, Boston Scientific, Natick, MA, USA)
was then advanced over the guidewire and into the
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cavity. In cases where second‑generation electrocautery
enhanced delivery system was used (Hot AXIOS™,
Boston Scientific, Natick, MA, USA), the LAMS catheter
advanced endoscopically into the WON cavity under EUS
guidance while current was applied to the diathermic tip
of the catheter.
Endoscopic transmural necrosectomy was performed on
either a scheduled basis or as clinically indicated, at the
discretion of the performing endoscopist. Necrosectomy
could be performed immediately following endoscopic
transmural drainage or delayed 1–2 weeks to allow
tract maturity. During necrosectomy, a forward‑viewing
gastroscope was advanced into the WON cavity through
the LAMS, and the cavity was then irrigated. Nasocystic
drains were used to irrigate the WON collection at the
discretion of the endoscopist.
RESULTS

Patient demographics and walled off necrosis
procedure characteristics

A total of 272 patients who underwent successful
EUS‑guided transmural drainage of WON using
LAMS from 2013 to 2016 at 8 centers were included
in this study. 136 patients used PPIs continuously
during the therapy (PPI group), and 136 patients were
not on PPIs during the interval of therapy (non‑PPI
group). The PPI and non-PPI groups were similar with
regards to age, gender, etiology of pancreatitis, cyst
size, and location [Table 1]. The mean patient age was
49.1‑year‑old, and the most common underlying etiology
of pancreatitis was gallstones (37.8%) followed by
alcohol (24.2%). The WON collections were located in
the pancreatic head in 15.1% patients and the body/tail
in 84.9% patients [Table 1].
With regards to stent placement, 231 patients underwent
transgastric LAMS placement while 41 patients
underwent transduodenal placement [Table 2]. The
diameters of the LAMS stents (either 10 mm or
15 mm) used for transmural WON drainage
were similar for the PPI and non‑PPI groups
(P = 0.19) [Table 2]. Disconnected pancreatic duct
syndrome was noted in 11.7% of patients resulting in
ERCP with PD stent placement.

Technical success and clinical outcomes

Technical success, as defined by successful access
and drainage of WON through the placement of a
LAMS, was not statistically different between the PPI
196

and non‑PPI groups (100.0% vs. 98.8% respectively;
P = 0.21) [Table 3]. Clinical success of the procedure
was defined as complete resolution of the WON
on follow‑up imaging, and no further endoscopic
procedure required. The PPI and non‑PPI groups
had similar clinical success rates (78.7% and 77.9%
respectively, P = 0.88). However, to achieve this clinical
success, the two groups required significantly different
numbers of DEN procedures. Not including the initial
LAMS placement, the PPI group required a median
of 4.6 procedures, compared to 3.2 in the non‑PPI
group (P < 0.01). The PPI group had 14.0% achieve
Table 1. Patient demographics and walled off
necrosis characteristics
Mean age (years)
Gender
Female
Male
Pancreatitis etiology
Gallstone
Alcohol
Idiopathic
Trauma
Other
WON location
Pancreatic head
Pancreatic body/tail
Mean WON long‑axis (mm)

PPI group (%)

Non‑PPI group (%)

48.4

51.5

44 (32.4)
92 (67.6)

52 (38.2)
84 (61.8)

46
30
25
15
24

(33.8)
(22.1)
(18.4)
(11.0)
(17.6)

57 (41.9)
36 (26.5)
16 (11.8)
12 (8.8)
15 (11.0)

22 (16.2)
114 (83.8)
116.2

19 (14.0)
117 (86.0)
122.6

PPI: Proton pump inhibitors, WON: Walled off necrosis

Table 2. Walled off necrosis procedure
characteristics
PPI group (%)

Non‑PPI group (%)

P

22 (16.2)
114 (83.8)

19 (14.0)
117 (86.0)

0.9

14 (10.3)
122 (89.7)
36

7 (5.1)
129 (94.8)
31

0.19

Site of
cyst‑enterostomy
Stomach
Duodenum
Axios diameter (mm)
10
15
Nasocystic tube
placement

0.57

PPI: Proton pump inhibitors

Table 3. Direct endoscopic necrosectomies
procedure outcomes
Technical
success (%)
Clinical
success (%)
Mean DEN
sessions

PPI group (n=136)

Non‑PPI group (n=136)

P

100.0

98.8

1

78.7

77.9

0.88

4.6

3.2

<0.01

DEN: Direct endoscopic necrosectomies, PPI: Proton pump inhibitors
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resolution after just the initial LAMS placement without
requiring subsequent procedures, compared to 22.1% in
the non‑PPI group, although this was not statistically
significant (P = 0.14).

Adverse events

Overall, the two groups had similar rates of adverse
events. The most common adverse events noted in
both groups were stent occlusion requiring endoscopic
clearance during subsequent necrosectomy (15.0%),
infection (8.8%), stent migration (4.7%), and
bleeding (4.4%) [Table 4]. When comparing the PPI vs.
non‑PPI groups, stent occlusion occurred significantly
more in the non‑PPI group (9.5% vs. 20.1%. P = 0.012).
Bleeding rates were similar between PPI and non‑PPI
groups (3.7% vs. 5.1% respectively, P = 0.79), as were
infection rates (5.8% vs. 11.7% P = 0.13) and stent
migration (7.4% vs. 2.2%, P = 0.056).
DISCUSSION
The use of LAMS is an effective technique for
resolving PFCs, including WONs.[6‑8] While surgical and
percutaneous approaches have their place in refractory
cases, the convenience and safety of an endoscopic
approach have made it the preferred first‑line therapy
for WON, and this practice has been supported by
large, randomized controlled trials.[9‑12] Several groups
have demonstrated high technical and clinical success
rates.[13‑19] However, despite the growing number of
physicians using LAMS drainage for WONs, the ideal
concomitant medical therapy remains unknown. In this
study, we aimed to investigate how the concurrent use
of acid suppression impacted the efficacy and adverse
event rates in LAMS for WONs.
Physiologically, arguments for both strategies can
be made. Continued production of stomach acid
which should, in theory, enter into the WON may
promote dissolution of solid necrotic debris, allow
solid contents to more easily pass through the LAMS
spontaneously to the stomach, and reduce the need
for endoscopic necrosectomy procedures. This should
also theoretically reduce the amount of devitalized
Table 4. Adverse events
GI bleeding
Infection
Stent occlusion
Stent migration

n (%)

PPI group

Non‑PPI group

P

12 (4.4)
24 (8.8)
41 (15.0)
13 (4.7)

5
8
13
10

7
16
28
3

0.79
0.13
0.012
0.056

PPI: Proton pump inhibitors, GI: Gastrointestinal

tissue thereby improving clinical success and stent
patency rates. Conversely, one could argue that the
suppression of gastric acid production may yield a
healthier communicating tract once LAMS has been
placed. With more acidic gastric contents, there could
theoretically be more adverse events such as ulceration
at the cystenterostomy site and an increased risk of
subsequent bleeding or even perforation.
Our study included 272 patients, all of whom received
LAMS for endoscopic resolution of WON. The
cohort was split into those receiving continuous PPI
therapy and those without. The two groups were
well matched with regards to demographics, etiology
of pancreatitis, WON location, and WON size. In
both PPI and non‑PPI groups, the technical success
rates were high (100.0% vs. 98.8% respectively), which
is comparable to prior studies investigating LAMS
placement for WON.[8‑14] Similarly, the two groups did
not have statistically significant differences in the rates
of clinical success (78.7% vs. 77.9%). This suggests that
acid suppression therapy is not necessarily integral to
the ultimate clinical success in the endoscopic treatment
of WON.
Of critical importance, although technical and clinical
success rates were similar in the two groups, the PPI
group required significantly more DEN procedures to
achieve this clinical success (4.6 vs. 3.2 procedures). To
the best of our knowledge, this is the first large study
to investigate the utility of acid suppression in these
patients. Our study suggests that acidic gastric contents
may confer a more potent clinical response in patients
with WON treated through LAMS whereas continuous
PPI therapy appears to decrease the per‑procedure
effectiveness. This could have considerable implications
for future treatment. While endoscopy is the preferred
method for treatment of WON, DEN procedures are
not without inherent risk. These results suggest that
withholding PPI therapy could potentially result in more
efficient treatment of WON.
Overall, the combined adverse event rates were similar
between the two groups. The non‑PPI group was
noted to have an overall significantly higher rate of
stent occlusion; the reasons for this are unclear but
may be due to more solid debris being liberated from
the WON cavity. Thus, while withholding PPI during
therapy would likely reduce the number of DEN, this
must be weighed against the increased risk of stent
occlusion.
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This is the first study to directly compare LAMS
procedures with and without PPI use, and the
optimization of medical therapy should continue to
be investigated. The strengths of this study include
the relatively large sample size, and the use of multiple
centers to gather patient data. A limitation of this
study was its retrospective nature. This imparts inherent
heterogeneity in the data including follow‑up time and
variability in endoscopic technique. Further investigation
with randomized prospective trials would be needed to
support our results.
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CONCLUSION
Overall, we have demonstrated that the use of PPI
therapy in patients being treated for WON with
LAMS and DEN reduces clinical efficacy and that
by withholding PPI we can decrease the total number
of DEN procedures required to resolve WON. PPI
use does appear to have an early protective effect
against the risk of stent occlusion, while the overall
adverse event rates appear to be similar. The results
of this study argue for the discontinuation of PPI
during endoscopic therapy for WON. Large‑scale
randomized controlled studies into this question are
warranted.
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